SHANGHAI SERUM BIO-TECHNOLOGY financial statements, including revenue, expenses, profit, and loss

The total revenue of 688163 for the last quarter is 74.72 M CNY, and it's 4.81% higher compared to the previous quarter. The net income of Q3 24 is 30.64 M CNY.